Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasagiline in Amyotrophic Lateral Sclerosis (ALS)
NCT01879241Phase 2Completed
- Sponsor
- Ulm University
- Start
- Jun 2013
- Primary completion
- Apr 2016
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rasagiline in amyotrophic lateral sclerosis (ALS), sponsored by Ulm University. Primary endpoint: Survival in ALS-Patients at 18 months. Started Jun 2013; status: completed.
02
Drugs
rasagiline
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT01879241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01879241.